Browse the evidence

Short-term green tea extract (GTE) supplementation (900 mg catechins/day for 7 days) reduces postexercise insulinemia following an oral glucose load without altering glucose appearance or disappearance rates, suggesting improved insulin sensitivity.

If you are sedentary and healthy, taking 900mg of green tea extract (standardized for catechins, specifically EGCG) daily for a week may help your body manage blood sugar better immediately after exercise. It won't change how much sugar enters your blood, but it will lower the amount of insulin your pancreas needs to secrete to handle that sugar. This effect is specific to the post-exercise window and may not occur at rest.

Significant initial weight loss (decrease in BMI) is a strong predictor of high adherence to liraglutide treatment.

If you experience significant weight loss in the first few months of liraglutide treatment, you are much more likely to stick with the medication long-term. This positive feedback loop is a key factor in maintaining adherence.

Higher socioeconomic status and non-smoking status are significantly associated with higher adherence to liraglutide treatment.

Patients with higher income/education levels and those who do not smoke are more likely to adhere to their liraglutide prescription. Addressing financial barriers and supporting smoking cessation may improve adherence rates.

Semaglutide 2.4 mg weekly reduces all-cause mortality and major adverse cardiovascular events in overweight/obese patients with preexisting cardiovascular disease but no diabetes, yet remains cost-ineffective at current pricing relative to standard care.

For a patient with heart disease and obesity but no diabetes: Semaglutide 2.4mg weekly significantly lowers your risk of heart attack, stroke, and death compared to standard care. However, because the drug is expensive, public health systems may not cover it unless the price drops. You should discuss the clinical benefits with your doctor, but be aware that insurance coverage might be denied or require prior authorization due to cost-effectiveness thresholds.

Long-term use of FDA-approved antiobesity medications (AOMs) for at least 112 days is associated with a statistically significant reduction in total health care costs and non-AOM medication costs by the second year of treatment compared to no treatment.

If you have obesity and are considering FDA-approved weight loss medications, discuss long-term coverage with your insurer. While the medication itself costs money, studies show that maintaining use for at least 112 days (approx. 4 months) can lead to significant reductions in other medical bills (like prescriptions for diabetes or blood pressure) by the second year, potentially saving money overall compared to not treating the obesity.

GIPR agonism mitigates the gastrointestinal adverse effects (nausea/vomiting) associated with GLP-1R agonism, thereby allowing for higher maximal tolerated doses of GLP-1-based therapies.

If you are struggling with nausea on a GLP-1 drug, switching to a combination GIP/GLP-1 drug might allow you to take a higher dose without more side effects. The GIP component helps cancel out the nausea caused by the GLP-1 component.

Tirzepatide, a dual GLP-1/GIP receptor agonist, demonstrates superior kidney and cardiovascular benefits compared to GLP-1 RAs alone, including significant reductions in albuminuria and eGFR decline.

Tirzepatide (Mounjaro/Zepbound) is a newer option that targets both GLP-1 and GIP hormones. It may offer better kidney and heart protection than older GLP-1 drugs. Discuss with your doctor if you have kidney disease, as it can slow kidney function decline significantly. It is also highly effective for weight loss.

Women benefit more than men from combined resistance exercise and protein supplementation in terms of relative leg strength improvements (leg press and leg extension), despite men showing greater absolute lean body mass gains.

Women in this study saw greater relative improvements in leg strength from the program than men, even though men gained more absolute muscle mass. Focus on your own progress and functional strength rather than comparing absolute mass to men.

Roux-en-Y gastric bypass (RYGB) reduces all-cause and cardiovascular mortality in obese individuals with type 2 diabetes primarily through weight reduction (BMI decrease), rather than through improvements in glycemic control (HbA1c), blood pressure, or lipid profiles.

For obese individuals with type 2 diabetes, Roux-en-Y gastric bypass significantly reduces the risk of death, primarily by lowering body weight. While blood sugar, blood pressure, and cholesterol often improve after surgery, these improvements do not appear to be the main reason for the longevity benefit. The weight loss itself is the key driver, acting as a proxy for reduced mechanical stress and inflammation. Therefore, achieving and maintaining significant weight loss is critical for mortality reduction in this population.

Combining a low-carbohydrate diet (approx. 50g carbs/day) with exercise (MICT or HIIT) significantly reduces anxiety levels in overweight young women, whereas the low-carbohydrate diet alone does not.

If you are overweight and feeling anxious, simply cutting carbs may not help your mental health and might even cause social stress. However, adding regular exercise (either moderate continuous cycling or high-intensity intervals) to a low-carb diet significantly reduces anxiety. Focus on the exercise component as the key driver for mental health benefits, not just the diet.

Adding exercise to a low-carbohydrate diet improves cardiorespiratory fitness (VO2peak) and reduces systolic blood pressure, but does not provide additional weight loss benefits compared to the low-carbohydrate diet alone.

If you are doing a low-carb diet, adding exercise won't necessarily make you lose weight faster than the diet alone. However, it will significantly improve your heart health, blood pressure, and mental well-being. Do exercise for these health benefits, not just for extra weight loss.

Oral ingestion of 15g essential amino acids (EAA) stimulates a greater insulin response compared to intravenous infusion of an equivalent dose, primarily mediated by the incretin hormone GIP, and this mechanism remains intact in older adults.

Consuming 15g of essential amino acids orally triggers a stronger insulin response than injecting the same amount, driven by gut hormones (specifically GIP). This 'incretin effect' helps manage blood sugar and remains effective in older adults, suggesting EAA supplementation can support metabolic health across the lifespan.

The brain utilizes two distinct, opponent neural networks to process food cues: a Limbic network that automatically encodes hedonic value (pleasantness/appetite), and a Prefrontal network that encodes regulatory information (healthfulness, processing level, and self-control requirements).

When you see food, your brain automatically splits the information: one part tells you how good it tastes (Limbic), and another tells you how processed/healthy it is (Prefrontal). To make better choices, consciously engage the Prefrontal network by focusing on the food's processing level or health attributes, rather than just fighting the taste. This leverages the brain's natural regulatory architecture.

GLP-1 receptor agonists (GLP-1RAs) induce significant weight loss, leading to improved physical functioning, daily living capacity, and mental well-being, despite common gastrointestinal side effects.

GLP-1RAs are effective for weight loss and improving daily functioning. Expect gastrointestinal side effects like nausea, which often subside after a few weeks. The benefits of weight loss and improved mobility often motivate patients to persist despite these side effects.

Female patients report greater benefits from GLP-1RA treatment compared to male patients, particularly in mental well-being and physical functioning.

Be aware that female patients may report greater improvements in quality of life and mental well-being from GLP-1RAs than male patients. This is a documented trend in patient experiences.

GLP-1RAs improve the management of sweet cravings and reduce emotional eating.

GLP-1RAs can help reduce sweet cravings and emotional eating, making it easier to maintain weight loss. This is a reported benefit by patients.

Acute exercise triggers the release of 'exerkines' (such as IL-6, BNP, and FGF21) from various tissues, which act as systemic signals to coordinate energy mobilization, metabolic adaptation, and cross-tissue communication.

Understand that your muscles and organs 'talk' to each other during exercise through chemical signals called exerkines. This is why exercise benefits not just the muscles working, but also your heart, brain, and metabolism. Consistent exercise ensures these beneficial signals are regularly released.

NuSH therapies induce significant weight loss that often includes loss of lean mass and skeletal muscle, creating a risk for sarcopenic obesity if body composition is not monitored.

Monitor your body composition, not just your weight. If you are on NuSHs, ensure your treatment plan includes resistance training and protein optimization to preserve muscle mass, as weight loss alone may hide muscle loss.

The semaglutide 2.4 mg single-dose pen-injector (SPI) demonstrates high ease-of-use and acceptability, with the vast majority of participants finding it easy to use and training, and preferring it over daily oral medication.

If you are considering semaglutide 2.4 mg via the single-dose pen, expect it to be easy to use. Most users found the training simple and the injection process easy. While some initial use errors (like seeing liquid on the skin) can occur, they are common in the first few injections and tend to disappear with practice. The device is generally preferred over daily pills due to its weekly frequency and ease of use.

Morbid obesity (BMI ≥40 kg/m2) in young adults (16-49 years) is associated with a massive loss of future life years (8.3 years) and high mortality risk, with 72% of deaths in this demographic linked to obesity.

For young adults with morbid obesity (BMI ≥40), the health risks are severe and immediate in terms of life expectancy. This group loses an average of 8.3 years of life, with 72% of deaths linked to obesity. Early intervention is critical to prevent premature mortality.

GLP-1 agonists (e.g., semaglutide, liraglutide) and metformin can aid in weight management, but GLP-1 agonists do not reset the weight set point, leading to significant weight regain upon discontinuation.

GLP-1 agonists and metformin can help with weight loss, but they do not cure the underlying biological tendency to regain weight. If you use them, expect to use them long-term to maintain results. They are tools to manage weight, not a one-time fix.

BCAA supplementation significantly increases strength gains (specifically bench press and squat 1RM) in men undergoing resistance training, with greater magnitude than in women.

If you are a male recreational weightlifter, adding a BCAA supplement (2.5g Leucine, 1.25g Isoleucine, 1.25g Valine daily) to your 4-day/week resistance training program may help you lift more weight, particularly in the bench press and squat, compared to training without it. This benefit appears stronger in men than in women.

A 12-month weight gain prevention intervention (Shape Program) significantly reduces depressive symptoms in socioeconomically disadvantaged, overweight/obese Black women compared to usual care, independent of weight change.

If you are a Black woman struggling with depression and weight concerns, consider a 'maintain, don't gain' approach. Focus on small, sustainable habits like daily walking and healthy eating without the pressure to lose weight. Regular check-ins with a health coach can provide social support and structure, which may significantly improve your mood independently of weight change.

Lorcaserin extended release (XR) 20 mg once daily is bioequivalent to lorcaserin immediate release (IR) 10 mg twice daily in terms of total exposure (AUC), offering a convenience advantage with potentially lower peak concentrations (Cmax).

If you are prescribed lorcaserin XR, take 20 mg once a day, with or without food. This formulation is designed to provide the same total amount of medication as the older twice-daily version but with a lower peak concentration, which may reduce side effects like headaches. Consistency is key; take it at the same time each day.